2006, Editrice Kurtis

Size: px
Start display at page:

Download "2006, Editrice Kurtis"

Transcription

1 Aging Clinical and Experimental Research Pharmacological treatment of Alzheimer s Disease* Angelo Bianchetti 1, Piera Ranieri 1, Alessandro Margiotta 1, and Marco Trabucchi 2 1 Department of Medicine, S. Anna Hospital, Brescia, 2 Geriatric Research Group, Brescia, Italy ABSTRACT. Background and aims: The treatment of Alzheimer s disease (AD) is a challenge for physician, families, and patients. An individualized, multimodal treatment plan addressing the treatment of cognitive, behavioural and functional decline is essential. Aim of the paper is to describe the principal components of the treatment plan of AD patients. Methods: A review of the recent literature was performed. Results: Acetylcholinesterase inhibitors (AChEIs) play an important role in the improvement of cognitive decline in mild to moderate AD, even if the improvement is not permanent. Data obtained from the CRONOS project (involving about 500 Alzheimer Evaluation Units) replicate in the real world those obtained in controlled trials, confirming that AD patients may benefit from AChEI treatment. Treatment of behavioral and psychological symptoms of dementia (BPSD) requires education of caregivers, non pharmacological interventions, identification and treatment of medical illnesses or environmental precipitating conditions, specific pharmacological treatment. Traditional neuroleptics are widely used for BPSD treatment, but limited data support their use, and side-effects are frequent and severe. Atypical antipsychotics are effective in treating BPSD, and safer than traditional neuroleptics. However, the increased risk of cerebrovascular accident in patients taking risperidone or olanzapine limited currently their use in demented subjects. The use of antidepressant drugs, as well as behavioral approach, may improve depressive symptoms frequently accompanying AD. Conclusions: Although at present there is no cure for AD, several drug treatments and care strategies may improve or stabilize cognitive and behavioral symptoms, and improve the quality of life of patients and families. (Aging Clin Exp Res 2006; 18: ) INTRODUCTION Pathways towards and away from Alzheimer's disease : this could be the title for a review on prevention and treatment of the silent epidemic of our times (1). In fact, although no current therapy can reverse the progressive cognitive and functional decline in Alzheimer s Disease (AD), several pharmacological substances and psychosocial techniques have been proven to be effective in reducing risk, slowing cognitive and functional decline, controlling behavioral symptoms, and improving quality of life of patients and caregivers (Table 1). Patients with dementia require an individualized, multimodal treatment plan: evolving with the progression of the illness, this can meet newly emerging issues, address the treatment of cognitive deficit and behavioral and psychological symptoms (BPSD), improve management of general medical conditions and complications, and enhance the education and counselling of caregivers and families. COGNITIVE DETERIORATION AS A PRIMARY OUTCOME OF TREATMENT Nowadays, strategies for primary therapy of AD are substantially limited to drugs improving central cholinergic neurotransmission, although a number of different drugs are under evaluation. The acetylcholinesterase inhibitors (AChEIs) are the most frequently used class of drugs for treating AD. Currently, second-generation AChEIs donepezil, galantamine and rivastigmine are marketed in Europe to treat the cognitive symptoms of mild to moderate AD. Daily treatment with donepezil is effective in the dose range 5 to 10 mg; rivastigmine in the range 6 to 12 mg; and galantamine in the range 16 to 24 mg. With some variability across studies, approximately twice as many patients who received active AChEIs had a four-point improvement on the ADAS- Cog with respect to patients receiving placebo (25-50% vs 15-25%), and approximately three times as many patients receiving AChEIs had a seven-point im- *This work was presented at the International Meeting - The Aging People, Pavia, 2-4 September Key words: Acetylcholinesterase inhibitors, Alzheimer s disease treatment, multidimensional approach, psychotropic drugs. Correspondence: A. Bianchetti, MD, Dept. of Medicine, S. Anna Hospital, via del Franzone 31, Brescia, Italy. angelo.bianchetti@grg-bs.it Received October 21, 2004; accepted in revised form May 30, Aging Clin Exp Res, Vol. 18, No. 2

2 Aging Clin Exp Res 18: , 2006 Alzheimer s disease treatment Table 1 - Proposed treatment options in Alzheimer s Disease. Outcome Treatment Prevention (or risk reduction) Antioxidants β-amyloid antagonists (secretase inhibitors, anti-aggregation compounds, amyloid vaccines) Anti-neurofibrillar drugs Genetic engineering Lipid-modifying agents (statins) Antihypertensive drugs Exercise Cognitive stimulation Delaying conversion MCI in AD Cholinesterase inhibitors Antioxidants (Ginko; Vitamin E) Improving symptoms Cholinesterase inhibitors Memantine Psychotropic drugs for behavior (antidepressants, atypical antipsychotics, anxiolytics, mood stabilizers, cholinesterase inhibitors) Cognitive rehabilitation techniques (reality orientation therapy, memory training) Behavioral management Family counselling and support Slowing progression Anti-oxidants (Ginko; Vitamin E) Hormones (estrogen) Neuroprotective agents (NGF) Reducing vascular risk (statins, homocysteine reduction) provement (12-20% vs 2-6% among those taking placebo) (2). All three drugs have a low incidence of serious reactions, commonly limited to cholinergic side-effects such as nausea, anorexia, vomiting and diarrhoea, as well as weight loss, insomnia, abnormal dreams, muscle cramps, bradycardia, syncope and fatigue. These drugs have similar cognitive efficacy (3). Some studies suggest that AChEIs improve cognition even in patients in more advanced phases of Alzheimer s Disease, and recent data indicate that donepezil is useful in reducing cognitive symptoms in mild cognitive impairment (4, 5). The improvement in cognitive or functional symptoms is not permanent, and the outcome of this treatment is a slowing in the progression of AD, corresponding to 8-12 months of the natural history of the disease. Studies also demonstrate that they may reduce the emergence of new behavioral disturbances and the need of institutionalization of AD patients, indicating a positive economic outcome (6, 7). The optimal duration of treatment with AChEIs is uncertain. Studies in which the rate of deterioration in the placebo group was extrapolated and compared with the level of function of patients continuing treatment suggest that patients continue to derive benefit from therapy for 2-3 years (2). Memantine, an N-methyl-D-aspartate antagonist, has recently been approved for treating moderate to severe AD (8). Placebo-controlled studies show the usefulness of memantine (alone, or in combination with AChEIs) in improving cognitive deficits and slowing functional deterioration in patients with moderate to severe AD. Clinical trials of other agents to improve cognitive function in AD are ongoing. These include estrogens, nonsteroidal anti-inflammatory agents, and botanic agents. The results of large-scale clinical trials using antioxidants (vitamin E, selegiline) show decreased rates of functional decline compared with placebo (9). Several strategies for the development of diseasemodifying treatment are under investigation, including antiamyloid therapies, neuroprotective agents, neurotrophic factors, antioxidants, anti-inflammatory, heavy metal chelators, but at the present time there are insufficient data to permit recommendations with respect to agents other than AChEIs and vitamin E (2). In March 2002, a phase IIa clinical trial of AD vaccine was stopped when sub-acute meningo-encephalitis developed in 18/298 cases (6%); post-hoc analysis indicated that those patients who generated Aβ antibodies had a reduction in disease progression (10). Researchers are investigating a new vaccination strategy, using safer immunogenic Aβ homologous peptides. THE ITALIAN CRONOS PROJECT EXPERIENCE With the aim of standardizing prescriptions of AChEIs and of assessing their effects on defined outcomes (cognition, functional status, behavior) in non-selected subjects, in October 2000 the Italian government started a national project called CRONOS, involving about 500 Alzheimer Evaluation Units (AEUs) and embracing all health districts (11). The project, besides adopting a definite attitude toward the reimbursement of AchEIs, aimed at building up a nationwide network of centers with a homogenous level of diagnostic and therapeutic competence. Much effort was expended with good results, since renewed organization of centers was stimulated, with standardized protocols and a data-base collected by the Ministry of Health. At the end of the project (March 2003), about 40,000 mild to moderate AD patients had been recruited. This pattern of prescription is lower than expected, revealing insufficient attention to early detection of the disease. We collected data from the AEUs of a northern Italy city (Cremona) on 1362 AD patients in the mild-moderate stage of the disease (mean age 77.4±6.9 years; 73.9% females; mean years of education 5.4±2.7; mean disease duration 26.9±15.7 months). Mean MMSE values in patients starting treatment were 19.2±3.9 at baseline, Aging Clin Exp Res, Vol. 18, No

3 A. Bianchetti, P. Ranieri, A. Margiotta, et al. Aging Clin Exp Res 18: , ±4.5 after three months (p<0.05, two-tailed t-test for paired samples) and 18.9±4.9 after 9 months (not significant at two-tailed t-test for paired samples vs baseline). Table 2 lists the clinical characteristics of the sample and main outcomes. Data replicated in the real world those obtained in controlled clinical trials. This fact further confirmed that non-selected AD patients with mild to moderate cognitive decline, seldom enrolled in randomized clinical trials, may benefit from AchEI treatment. The specific role of drugs when compared with the positive effects exerted by the care given at AEUs remains to be clarified. In the near future, the AEU system will be in charge in data monitoring on the efficacy and risk ratio of atypical antipsychotics in dementia. MANAGEMENT OF BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD) Treatment of BPSD is often challenging, and requires education of family members/caregivers and good communication between all persons involved in patient care, in addition to standard pharmacological and non-pharmacological interventions. In general, non-pharmacological approaches are the first-line treatment for BPSD, but for moderate or severe symptoms, medication is clearly indicated. Treatment should first be directed at identifying precipitants or undiagnosed medical illnesses or environmental antecedents, which should be corrected or eliminated. Traditional neuroleptics are the most common psychotropic medication prescribed for BPSD, and even limited data support their use, burdened by a high frequency of side-effects (12). There are open-label studies, case reports and recent placebo-controlled studies suggesting that atypical antipsychotics (clozapine, riperidone, olanzapine, quetiapine) are effective in treating BPSD and safer than older drugs (13). However, currently, no atypical antipsychotic is licensed specifically for the treatment of behavioral disturbances in dementia. Clozapine is highly effective in treating psychosis in patients with Parkinson s disease, but data on the treatment of behavioral disturbances in AD are very limited (14). Clozapine has significant side-effects, including agranulocytosis (in the USA, the implementation of the national registry system has reduced mortality related to agranulocytosis from 15 to 3%), sedation, seizures, hypotension and weight gain, discouraging use in AD (15, 16). Significant evidence demonstrates the efficacy of risperidone in BPSD treatment, even at low dosages (1-2 mg/day) (17, 18). The side-effects of risperidone include insomnia, hypotension, weight gain, and extrapyramidal symptoms (particularly for dosages greater than 6 mg/day) (16). Studies indicate that olanzapine is effective in BPSD, at dosages ranging from 1.25 mg to 5 mg/day (19). Common side-effects of olanzapine include sedation, orthostatic hypotension, seizures and weight gain. Olanzapine may increase motor symptoms in Parkinson s disease and worsen glycemic control in diabetic patients (16). Quetiapine has been shown to improve BPSD and be safe in AD, but available data are limited (20). Quetiapine should be initiated at a dosage of 12.5 mg at bedtime and titrated every five days until the desired effect is achieved (dosages range from 25 to 200 mg/day). Common side-effects include sedation, headache and orthostatic hypotension. In March 2004, after analyzing data from randomized placebo-controlled clinical trials and finding an increased risk of cerebrovascular adverse events in patients taking risperidone or olanzapine compared with placebo (OR 2.9 and 4.8 respectively), the regulatory agencies of some countries recommended that these two drugs should not be used to treat behavioral symptoms of dementia. In spite of this information, recent data demonstrate that the use of traditional neuroleptics in treating BPDS is associated with a greater risk of cerebrovascular accidents than that of atypical antipsychotics (21). AD patients with depressive symptoms should be considered for treatment, although they do not meet the classic nosographic criteria for depressive symptoms. Behavioral approaches (psychotherapy, activity groups, exercise, pets) may be useful (22). When medical treatment is indicated, the choice of drugs should be based on the patient s general medical condition and co-existing behavioral symptoms. Low doses of serotonin re-uptake inhibitors (particularly sertraline and citalopram) are the Table 2 - Clinical characteristics at baseline of 1362 patients enrolled in Piano Alzheimer project in Cremona (Northern Italy). Age (years) 77.4±6.9 [48-95] Sex (% female) 73.9 Education (years) 5.4±2.7 [0-21] Disease duration (months) 26.9±15.7 [5-96] Co-occurrent chronic diseases [0-4] None (%) or more (%) 59.0 MMSE score at baseline 19.2±3.9 [10-26] ADL (preserved) 4.8±1.5 [0-6] IADL (preserved) 3.8±2.6 [0-8] Previous use of AChEIs (%) 38.6 Delta MMSE after 9 months of treatment* <0 37.0% % % 4 or more 13.8% *Delta MMSE indicates improvement in MMSE score; level <0 indicates proportion of subjects whose scores worsened. 160 Aging Clin Exp Res, Vol. 18, No. 2

4 Aging Clin Exp Res 18: , 2006 Alzheimer s disease treatment most appropriate first-line agents (23). Combined serotonin- and noradrenergic re-uptake inhibitors are commonly used as second-line agents (24). Tricyclic antidepressants are effective treating depression, but have significant anticholinergic activity (especially amitriptyline, imipramine and clorimipramine) and should be used with caution in dementia (25). In the management of BPSD, non-pharmacological interventions may play an important role. Our group recently demonstrated that, in a protected environment (i.e., a rehabilitative ward specifically devoted to the treatment of severely demented subjects), NPI scores in a large group of patients could be significantly reduced, even after reducing the proportion of subjects treated with atypical neuroleptics. This preliminary observation further strengthens the need for a differentiated approach to BPSD, involving drug treatment but also giving attention to clinical, psychological and environmental stressors (26). CONCLUSIONS Although at present there is no cure for Alzheimer s disease, several drug treatments and care strategies may improve or stabilize cognitive and behavioral symptoms, and improve the quality of life of patients and families. Several agents that can slow the progression of the disease or delay its onset (such as growth factors, antiamyloid therapies, neuroprotective strategies, antioxidants, vaccination) are in development and clinical testing but, for the moment, the outcome of treatment is restricted to slowed cognitive and functional decline and improved BPSD (27). Optimal treatment of demented patients needs a comprehensive approach, specific programs and services. Among the pharmacological approaches to AD, a peculiar role must be given to the treatment of somatic diseases. In the early stages of AD, the control of diseases such as hypertension, diabetes and other chronic medical conditions may influence the clinical presentation of the symptoms of dementia; cognitive deficits also have an effect on awareness of symptoms and on compliance with treatment (28). As AD progresses, various conditions develop which may lead to death, such as pneumonia and upper respiratory infections, nutritional disorders, pressure sores, fractures and wounds. Management of these conditions in severely demented subjects induces significant clinical and ethical dilemmas (29). A clear definition of realistic outcomes of treatment, regular follow-ups using standardized measures to detect efficacy of treatment, and support and counselling of caregivers are essential for both clinical and health policy purposes. The results of studies conducted in the real world demonstrate that the improved quality of life of demented patients and their families is a reasonable outcome of treatment (7). REFERENCES 1. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004; 430: Cummings JL. Alzheimer s disease. N Engl J Med 2004; 351: Ritchie CW, Ames D, Clayton T, Lai R. Meta-analysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer Disease. Am J Geriatr Psychiatry 2004; 12: Bullock R, Hammond G. Realistic expectations. The management of severe Alzheimer Disease. Alzheimer Dis Assoc Disord 2003; 17: S Salloway S, Ferris S, Kluger A, et al. Donepezil 401 Study Group. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 2004; 63: Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003; 289: Bianchetti A, Trabucchi M. Health services and economic perspectives in Alzheimer Disease. It J Psychiatry Behav Sci 2003; 13: Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer s disease. N Engl J Med 1997; 336: Hock C, Konietzko U, Streffer JR, et al. Antibodies against betaamyloid slow cognitive decline in Alzheimer's Disease. Neuron 2003; 38: Bianchetti A, Padovani A, Trabucchi M. Outcomes of Alzheimer's disease treatment: the Italian CRONOS project. Int J Geriatr Psychiatry 2003; 18: Devanand DP, Marder K, Michaels KS, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry 1998; 155: Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004; 329: Hoeh N, Gyulai L, Weintraub D, Streim J. Pharmacologic management of psychosis in the elderly: a critical review. J Geriatr Psychiatry Neurol 2003; 16: Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998; 59: Motsinger CD, Perron GA, Lacy TJ. Use of atypical antipsychotic drugs in patients with dementia. Am Fam Physician 2003; 67: Rabinowitz J, Katz IR, De Deyn PP, Brodaty H, Greenspan A, Davidson M. Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. J Clin Psychiatry 2004; 65: Brodaty H, Ames D, Snowdon J, et al. A randomized placebocontrolled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64: Aging Clin Exp Res, Vol. 18, No

5 A. Bianchetti, P. Ranieri, A. Margiotta, et al. Aging Clin Exp Res 18: , Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000; 57: Fujikawa T, Takahashi T, Kinoshita A, et al. Quetiapine treatment for behavioral and psychological symptoms in patients with senile dementia of Alzheimer type. Neuropsychobiology 2004; 49: Herrmann N, Mamdani M, Lanctôt KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161: Teri L. Behavioral treatment of depression in patients with dementia. Alzh Dis Assoc Disord 1994; 8: Lyketsos CG, Lee HB. Diagnosis and treatment of depression in Alzheimer s Disease. A practical update for the clinician. Dement Geriatr Cogn Disord 2004; 17: Alexopoulos GC, Katz IR, Reynolds CF, Carpenter D, Docherty JP: Pharmacotherapy of depressive disorders in older patients. A Postgraduate Medicine Special Report. Minneapolis, Minn: Mc- Graw Hill, Cummings JL. Alzheimer s Disease. N Engl J Med 2004; 351: Bianchetti A, Trabucchi M. Behavioural and psychological symptoms of dementia: clinical aspects. Neurosci Res Commun 2004; 35: Bianchetti A, Trabucchi M. Clinical aspects of Alzheimer's disease. Aging Clin Exp Res 2001; 13: Bianchetti A, Frisoni GB, Trabucchi M. Do old age psychiatrists miss physical illnesses? Int J Geriatr Psychiatry 1993; 8: Rozzini R, Sabatini T, Trabucchi M. Medical treatment of acute illnesses in end-stage dementia. Arch Intern Med 2003; 163: Aging Clin Exp Res, Vol. 18, No. 2

Psychosis and Agitation in Dementia

Psychosis and Agitation in Dementia Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University

More information

Neurocognitive Disorders Research to Emerging Therapies

Neurocognitive Disorders Research to Emerging Therapies Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia

More information

Dementia Pharmacotherapy

Dementia Pharmacotherapy Dementia Pharmacotherapy 1 early therapeutic interventions can maximize pharmacologic efficacy with these agents 2 Selecting a Medication Not enough evidence to recommend one agent over another based on

More information

DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future

DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future Daniel S. Sitar Professor Emeritus University of Manitoba Email: Daniel.Sitar@umanitoba.ca March 6, 2018 INTRODUCTION EPIDEMIOLOGY

More information

PDFlib PLOP: PDF Linearization, Optimization, Protection. Page inserted by evaluation version

PDFlib PLOP: PDF Linearization, Optimization, Protection. Page inserted by evaluation version PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version www.pdflib.com sales@pdflib.com doi:10.1111/j.1479-8301.2007.00215.x PSYCHOGERIATRICS 2008; 8: 32 37 REVIEW

More information

Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD

Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, M.D. Health Sciences

More information

Psychotropic Strategies Handout Package

Psychotropic Strategies Handout Package Psychotropic Strategies Handout Package Psychotropic Strategies Learning Objectives Utilize all clinical information available Assess the patient s overall condition this is essential Basic Principles

More information

Pharmacological Treatment of Aggression in the Elderly

Pharmacological Treatment of Aggression in the Elderly Pharmacological Treatment of Aggression in the Elderly Howard Fenn, MD Adjunct Clinical Associate Professor Department of Psychiatry and Behavioral Sciences Stanford University Self-Assessment Question

More information

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that

More information

ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good?

ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good? ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good? STEPHANIE M. OZALAS, PHARMD, BCPS, BCGP VA MARYLAND HEALTH CARE SYSTEM BALTIMORE, MD DISCLOSURES Off-label use of medications will be

More information

Alzheimer s Disease. Pathophysiology: Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior,

Alzheimer s Disease. Pathophysiology: Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior, 2 Alzheimer s Disease Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior, and functional status with no known cause or cure. Patients eventually lose cognitive, analytical,

More information

Up to 90% of people with dementia experience

Up to 90% of people with dementia experience Focus on CME at the University of Calgary Getting Aggressive with Dementia Adrienne Cohen, MD, BSc, FRCPC Presented at Behaviour Problems in the Elderly, video-audio conference, 2003 Up to 90% of people

More information

Cognitive enhancers PINCH ME. Anticholinergic burden BPSD. Agitation, Aggression and antipsychotics

Cognitive enhancers PINCH ME. Anticholinergic burden BPSD. Agitation, Aggression and antipsychotics Cognitive enhancers PINCH ME Anticholinergic burden BPSD Agitation, Aggression and antipsychotics 2 types Cholinesterase inhibitors licensed for mild to moderate AD Donepezil Galantamine Rivastigmine also

More information

Antipsychotic Medications

Antipsychotic Medications TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood

More information

MEDICATIONS IN MANAGING DIFFICULT BEHAVIORS

MEDICATIONS IN MANAGING DIFFICULT BEHAVIORS MEDICATIONS IN MANAGING DIFFICULT BEHAVIORS A REALITY CHECK reality check Noun informal an occasion on which one is reminded of the state of things in the real world. ROBERT LACOSTE, MD MEDICAL DIRECTOR,

More information

Any interventions, where RCTs in PD are not available, are not included in the tables.

Any interventions, where RCTs in PD are not available, are not included in the tables. Tables Interventions where new studies have been published are indicated in bold italics. Changes in conclusions are indicated in italics and are highlighted in yellow. Any interventions, where RCTs in

More information

Disclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA

Disclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer

More information

NeuroPharmac Journal ISSN: Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M.

NeuroPharmac Journal ISSN: Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M. ISSNISSN ISSN: 2456-3927 NeuroPharmac Journal Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M. Alshahrani www. neuropharmac.com Jan-April 2018, Volume 3, Issue

More information

USING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE?

USING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE? USING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE? Mugdha Thakur, MD Associate Professor of Psychiatry and Behavioral Sciences Duke University

More information

Drug Update. Treatments for Cognitive Impairment in the Older Adult. William Solan, M.D. Karen Sanders, Ph.D. Northwest Hospital Seattle

Drug Update. Treatments for Cognitive Impairment in the Older Adult. William Solan, M.D. Karen Sanders, Ph.D. Northwest Hospital Seattle Drug Update Treatments for Cognitive Impairment in the Older Adult William Solan, M.D. Karen Sanders, Ph.D. Northwest Hospital Seattle Current Drug Treatments for Alzheimer s Disease Cholinesterase Inhibitors:

More information

Diagnosis and Treatment of Alzhiemer s Disease

Diagnosis and Treatment of Alzhiemer s Disease Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised

More information

The place for treatments of associated neuropsychiatric and other symptoms

The place for treatments of associated neuropsychiatric and other symptoms The place for treatments of associated neuropsychiatric and other symptoms Luca Pani dg@aifa.gov.it London, 25 th November 2014 Workshop on Alzheimer s Disease European Medicines Agency London, UK Public

More information

Month/Year of Review: September 2013 Date of Last Review: February 2012

Month/Year of Review: September 2013 Date of Last Review: February 2012 Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights

More information

Alzheimer dementia: Starting, stopping drug therapy

Alzheimer dementia: Starting, stopping drug therapy REVIEW LUKE D. KIM, MD, FACP, CMD Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Center for Geriatric Medicine, Medicine

More information

Pharmacotherapeutic aspects of dementia care in Malta

Pharmacotherapeutic aspects of dementia care in Malta Review Article Pharmacotherapeutic aspects of dementia care in Malta Charles Scerri, Stephen Abela, Anthea Innes Abstract Dementia is the most common neurodegenerative disorder of old age affecting one

More information

Known as both a thief and murderer,

Known as both a thief and murderer, &A Dementia Drugs: When Should They Be Stopped? Ron Keren, MD, FRCPC As presented at the University of Toronto s Primary Care Conference, Toronto, Ontario (May 25) Known as both a thief and murderer, Alzheimer

More information

Clinical practice with antidementia and antipsychotic drugs: Audit from a geriatric clinic in India

Clinical practice with antidementia and antipsychotic drugs: Audit from a geriatric clinic in India Indian J Psychiatry. 2009 Oct-Dec;; 51(4): 272 275. doi: 10.4103/0019-5545.58292 PMCID: PMC2802374 Clinical practice with antidementia and antipsychotic drugs: Audit from a geriatric clinic in India 1

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (Review of TA 111) Appraisal

More information

Outlines! Current Issue in Management. of Dementia! Cholinesterase Inhibitors! Medications that soon to be used in. Papan Thaipisuttikul, M.D.

Outlines! Current Issue in Management. of Dementia! Cholinesterase Inhibitors! Medications that soon to be used in. Papan Thaipisuttikul, M.D. Current Issue in Management of Dementia! Papan Thaipisuttikul, M.D. Department of Psychiatry Ramathibodi Hospital! Outlines! Current medications use in dementia management in Thailand. Medications that

More information

BEHAVIORAL PROBLEMS IN DEMENTIA

BEHAVIORAL PROBLEMS IN DEMENTIA BEHAVIORAL PROBLEMS IN DEMENTIA CLINICAL FEATURES Particularly as dementia progresses, psychiatric symptoms may develop that resemble discrete mental disorders such as depression or mania The course and

More information

Psychotropic Medication Use in Dementia

Psychotropic Medication Use in Dementia Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,

More information

Literature Scan: Alzheimer s Drugs

Literature Scan: Alzheimer s Drugs Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Medications for treating people with dementia: summary of evidence on cost-effectiveness

Medications for treating people with dementia: summary of evidence on cost-effectiveness Medications for treating people with dementia: summary of evidence on cost-effectiveness Martin Knapp, A-La Park and Alistair Burns PSSRU, London School of Economics and Political Science v4 23 July 2017

More information

11/11/2016. Disclosures. Natural history of BPSD. Objectives. Assessment of BPSD. Behavioral Management of Persons with Alzheimer s Disease

11/11/2016. Disclosures. Natural history of BPSD. Objectives. Assessment of BPSD. Behavioral Management of Persons with Alzheimer s Disease Disclosures Behavioral Management of Persons with Alzheimer s Disease Wisconsin Association of Medical Directors November 17, 2016 Art Walaszek, M.D. Professor of Psychiatry UW School of Medicine & Public

More information

COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK

COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK Robert L Alesiani, PharmD, CGP Chief Pharmacotherapy Officer CareKinesis, Inc. (a Tabula Rasa Healthcare Company) 2 3 4 5 Pharmacogenomics

More information

8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research

8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event

More information

Pharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital

Pharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital Pharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital with thanks to Jonathan Cavan for his input Aims Define BPSD and common symptoms

More information

Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease

Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Professor Clive Ballard Dr Byron Creese University of Exeter, UK Guardian guide for 2018: Top

More information

Atypical Antipsychotics and the Risk of Diabetes in an Elderly Population in Long-Term Care: A Retrospective Nursing Home Chart Review Study

Atypical Antipsychotics and the Risk of Diabetes in an Elderly Population in Long-Term Care: A Retrospective Nursing Home Chart Review Study Atypical Antipsychotics and the Risk of Diabetes in an Elderly Population in Long-Term Care: A Retrospective Nursing Home Chart Review Study Stewart G. Albert, MD, George T. Grossberg, MD, Papan J. Thaipisuttikul,

More information

The Psychopharmacology of Alzheimer s Disease. Bruce Kaster, MD Instructor in Psychiatry Harvard Medical school

The Psychopharmacology of Alzheimer s Disease. Bruce Kaster, MD Instructor in Psychiatry Harvard Medical school The Psychopharmacology of Alzheimer s Disease Bruce Kaster, MD Instructor in Psychiatry Harvard Medical school Overview of Alzheimer s Disease Alzheimer s is a progressive degenerative disease Prevalence

More information

Dementia and Fall Geriatric Interprofessional Training. Wael Hamade, MD, FAAFP

Dementia and Fall Geriatric Interprofessional Training. Wael Hamade, MD, FAAFP Dementia and Fall Geriatric Interprofessional Training Wael Hamade, MD, FAAFP Prevalence of Dementia Age range 65-74 5% % affected 75-84 15-25% 85 and older 36-50% 5.4 Million American have AD Dementia

More information

November 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by

November 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by November 16-18, 2017 Hotel Monteleone New Orleans, LA Provided by Major Neurocognitive Disorder: The Beginning and the End. Making the Diagnosis and Addressing Distressing Behavior W. Vaughn McCall, MD,

More information

The most common cause of dementia in the elderly is. Cholinesterase Inhibitors in the Treatment of Dementia REVIEW ARTICLE. Jay M.

The most common cause of dementia in the elderly is. Cholinesterase Inhibitors in the Treatment of Dementia REVIEW ARTICLE. Jay M. Cholinesterase Inhibitors in the Treatment of Dementia Jay M. Ellis, DO Dementia associated with probable Alzheimer s disease (AD) is one of the most common types of dementia. Patients with AD often have

More information

Management of Agitation in Dementia. Kimberly Triplett Ferguson, MS4

Management of Agitation in Dementia. Kimberly Triplett Ferguson, MS4 Management of Agitation in Dementia Kimberly Triplett Ferguson, MS4 Objectives 1. Review recommended evaluation of agitated patients with dementia. 2. Discuss evidence concerning nonpharmacologic management.

More information

A Basic Approach to Mood and Anxiety Disorders in the Elderly

A Basic Approach to Mood and Anxiety Disorders in the Elderly A Basic Approach to Mood and Anxiety Disorders in the Elderly November 1 2013 Sarah Colman MD FRCPC Clinical Fellow, Geriatric Psychiatry Mount Sinai Hospital, University of Toronto Disclosure No conflict

More information

Management of the Acutely Agitated Long Term Care Patient

Management of the Acutely Agitated Long Term Care Patient Management of the Acutely Agitated Long Term Care Patient 80 60 Graying of the Population US Population Over Age 65 Millions of Persons 40 20 0 1900 1920 1940 1960 1980 1990 2010 2030 Year Defining Dementia

More information

Current Treatments for Dementia and Future Prospects. James Warner St Charles Hospital, London

Current Treatments for Dementia and Future Prospects. James Warner St Charles Hospital, London Current Treatments for Dementia and Future Prospects James Warner St Charles Hospital, London Dementia Cognitive Non-cognitive (BPSD) Memory orientation language other cognitive abilities praxis planning

More information

Rational Medication Use in Dementia

Rational Medication Use in Dementia Rational Medication Use in Dementia Stephen Thielke sthielke@u.washington.edu (206) 764 2815 I have no conflicts of interest to report. I am an employee of the federal government. The opinions in this

More information

Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)

Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Issue date: November 2006 (amended September 2007) Review date: September 2009 Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a

More information

Alzheimer s disease. The facts in brief

Alzheimer s disease. The facts in brief Alzheimer s disease Dementia is an umbrella term used to describe various conditions which damage brain cells and lead to a loss of brain function over time. Dementia causes a progressive decline in a

More information

Behavioral and Psychological Symptoms of dementia (BPSD)

Behavioral and Psychological Symptoms of dementia (BPSD) Behavioral and Psychological Symptoms of dementia (BPSD) Chris Collins - Old Age Psychiatrist, Christchurch chris.collins@cdhb.health.nz Approaching BPSD: the right mindset Assessment Non-drug management

More information

Introduction to Drug Treatment

Introduction to Drug Treatment Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical

More information

ALZHEIMER S DISEASE OVERVIEW. Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health

ALZHEIMER S DISEASE OVERVIEW. Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health ALZHEIMER S DISEASE OVERVIEW Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health Prevalence AD: DEMOGRAPHY AND CLINICAL FEATURES Risk and protective factors Clinical features and

More information

Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia

Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia This prescribing guideline provides the necessary information and guidance to support clinicians in the

More information

The prevalence of dementia increases from. Pharmacological management of behavioural disturbance in patients with dementia. Dementia.

The prevalence of dementia increases from. Pharmacological management of behavioural disturbance in patients with dementia. Dementia. Dementia Pharmacological management of behavioural disturbance in patients with dementia Management of behavioural disturbance in the setting of dementia can be challenging. There are many potential causes

More information

Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217

Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217 NICE 2017. All rights reserved.

More information

Dementia of the Alzheimer Type: the Drug Treatment Debate

Dementia of the Alzheimer Type: the Drug Treatment Debate Dementia of the Alzheimer Type: the Drug Treatment Debate I have no financial conflict of interest. Many years ago I was given a trip to San Fran and taught to use a slide set from the drug company. I

More information

HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE?

HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE? EAMA CORE CURRICULUM HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE? Sofia Duque Orthogeriatric Unit São Francisco Xavier Hospital Occidental Lisbon Hospital Center University Geriatric Unit, Faculty of

More information

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution

More information

Assessment and management of behavioral and psychological symptoms of dementia

Assessment and management of behavioral and psychological symptoms of dementia Assessment and management of behavioral and psychological symptoms of dementia Helen C Kales, 1 2 3 Laura N Gitlin, 4 5 6 Constantine G Lyketsos 7 1 Section of Geriatric Psychiatry, Department of Psychiatry,

More information

Psychotropic Medication Use in Canadian Long-Term Care Patients Referred for Psychogeriatric Consultation

Psychotropic Medication Use in Canadian Long-Term Care Patients Referred for Psychogeriatric Consultation Original Research Psychotropic Medication Use in Canadian Long-Term Care Patients Referred for Psychogeriatric Consultation Corinne E. Fischer, MD 1,2,3, Carole Cohen, MD 3,4, Lauren Forrest, BSc 3, Tom

More information

MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA

MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA Dr. Dallas Seitz MD PhD FRCPC Associate Professor and Division Chair, Division of Geriatric Psychiatry Department of Psychiatry, Queen s University President,

More information

Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer s disease: A meta-analysis

Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer s disease: A meta-analysis ORIGINAL RESEARCH Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer s disease: A meta-analysis Noll Campbell 1 Amir Ayub 2 Malaz A Boustani 2 Chris Fox 3 Martin

More information

Recommendations For the Use of Donepezil

Recommendations For the Use of Donepezil Recommendations For the Use of Donepezil The trial of donepezil in patients with mild to moderate dementia due to probable AD was one recommendation made by the Canadian Consensus Conference on Dementia.

More information

Pharmacy Drug Class Review

Pharmacy Drug Class Review April 16, 2010 Pharmacy Drug Class Review Disclaimer: Specific agents may have variations Dementia Review Focus on available treatments for Alzheimer s disease Authored By: Sarah Davis, Pharm.D Candidate

More information

Appendix N: Research recommendations

Appendix N: Research recommendations Appendix N: recommendations N.1 First-line treatment of motor symptoms recommendation 1 Interventions What is the effectiveness of initial levodopa monotherapy versus initial levodopa-dopamine agonist

More information

From MCI to Dementia DR YU- MIN LIN GERIATRICIAN AUG 2018

From MCI to Dementia DR YU- MIN LIN GERIATRICIAN AUG 2018 From MCI to Dementia DR YU- MIN LIN GERIATRICIAN AUG 2018 Overview What is dementia? Common causes Normal cognitive decline Abnormal decline and mild cognitive impairment How do we manage dementia Can

More information

KEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.

KEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected. KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised

More information

Interface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE

Interface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE Cholinesterase inhibitors and Memantine are now classified as green (following specialist initiation) drugs by the Greater Manchester Medicines Management Group. Who will diagnose and decide who is suitable

More information

The Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia

The Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia Disclosures Research support, Parkinson Society Canada, Canadian Institutes of Health Research, Ministry of Economic Development and Innovation, Teva Novartis clinical trial, Principal Investigator CME

More information

Treatment of behavioral and psychological symptoms of dementia: a systematic review

Treatment of behavioral and psychological symptoms of dementia: a systematic review Psychiatr. Pol. 2016; 50(4): 679 715 PL ISSN 0033-2674 (PRINT), ISSN 2391-5854 (ONLINE) www.psychiatriapolska.pl DOI: http://dx.doi.org/10.12740/pp/64477 Treatment of behavioral and psychological symptoms

More information

Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017

Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017 Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist HMS Training Webinar January 27, 2017 1 Describe nationwide prevalence and types of elderly dementia + define BPSD Define psychotropic

More information

Appendix 2 (continued): Recommendations for the management of mild to moderate dementia, dementia with a cerebrovascular component, and for addressing

Appendix 2 (continued): Recommendations for the management of mild to moderate dementia, dementia with a cerebrovascular component, and for addressing a cerebrovascular component, and for addressing ethical issues in dementia (page 1 of 7) Mild to moderate dementia 1. Most patients with dementia can be assessed and managed adequately by their primary

More information

Medications used in dementia: a review of evidence

Medications used in dementia: a review of evidence Medications used in dementia: a review of evidence Review paper Medications used in dementia: a review of evidence C Suraweera, R Hanwella, VA de Silva Background Dementia is an acquired global impairment

More information

Antipsychotics for Dementia Under Control or Over-Prescribed?

Antipsychotics for Dementia Under Control or Over-Prescribed? Antipsychotics for Dementia Under Control or Over-Prescribed? Nathaniel Hedrick, PharmD ProCare HospiceCare, Manager of Clinical Services Learning Objectives Summarize the disease progression and most

More information

RESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH

RESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH EADC BRUNO VELLAS 14/01/05 10:14 Page 1 EADC OVERVIEW B. VELLAS & E. REYNISH (Toulouse, France, EU) Bruno Vellas: The European Alzheimer's Disease Consortium is a European funded network of centres of

More information

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA 111)

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA 111) National Institute for Health and Clinical Excellence Health Technology Appraisal Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA 111) Response

More information

Dementia is a common neuropsychiatric disorder characterized by progressive impairment of

Dementia is a common neuropsychiatric disorder characterized by progressive impairment of Focused Issue of This Month Diagnosis and Treatment for Behavioral and Psychological Symptoms of Dementia Byoung Hoon Oh, MD Department of Psychiatry, Yonsei University College of Medicine E - mail : drobh@yuhs.ac

More information

CHCS. Multimorbidity Pattern Analyses and Clinical Opportunities: Dementia. Center for Health Care Strategies, Inc. FACES OF MEDICAID DATA SERIES

CHCS. Multimorbidity Pattern Analyses and Clinical Opportunities: Dementia. Center for Health Care Strategies, Inc. FACES OF MEDICAID DATA SERIES CHCS Center for Health Care Strategies, Inc. FACES OF MEDICAID DATA SERIES Multimorbidity Pattern Analyses and Clinical Opportunities: Dementia December 2010 Cynthia Boyd, MD, MPH* Bruce Leff, MD* Carlos

More information

WHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together. Presented by

WHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together. Presented by WHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together Presented by Our agenda for today Understanding behavioral symptoms in people living with dementia Briefly review key strategies

More information

Dementia. patient, or. individuals whose treatment regimes have been initiated and stabilized by the hospital-based dementia specialist.

Dementia. patient, or. individuals whose treatment regimes have been initiated and stabilized by the hospital-based dementia specialist. DEMENTIA UNIT NO. 3 PHARMACOLOGICAL TREATMENT OF DEMENTIA Dr Lim Wee Shiong ABSTRACT Pharmacotherapy is a vital part of the multi-pronged strategy in dementia management. All dementia patients should be

More information

Dementia NICE Guidelines Update. Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018

Dementia NICE Guidelines Update. Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018 Dementia NICE Guidelines Update Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018 How NICE guidelines are reviewed Multidisciplinary guideline committee established Review

More information

COGNOS. Care for people with Cognitive dysfunction A National Observational Study. Professor Dr Jan De Lepeleire COGNOS members

COGNOS. Care for people with Cognitive dysfunction A National Observational Study. Professor Dr Jan De Lepeleire COGNOS members COGNOS Care for people with Cognitive dysfunction A National Observational Study Professor Dr Jan De Lepeleire COGNOS members Luxembourg Alzheimer Europe 2010 The Careplan in Belgium Requirements for reimbursement

More information

Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches

Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches Andrea Iaboni, MD, DPhil, FRCPC Toronto Rehab Institute, UHN Learning objectives Recognize

More information

DEMENTIA AND MEDICATION

DEMENTIA AND MEDICATION DEMENTIA AND MEDICATION Dr. Siobhan Ni Bhriain, MRCP, MRCPsych. Clinical Director, Tallaght and SJH MHS, Consultant Old Age Psychiatrist, Chair, DSIDC Steering Committee. SUMMARY OF TODAY S TALK Dementia-definition,

More information

Depression in Late Life

Depression in Late Life Depression in Late Life Robert Madan MD FRCPC Geriatric Psychiatrist Key Learnings Robert Madan MD FRCPC Key Learnings By the end of the session, participants will be able to List the symptoms of depression

More information

Dementia and Cognition in Older Adults: Year in Review

Dementia and Cognition in Older Adults: Year in Review Dementia and Cognition in Older Adults: Year in Review 2008 2009 Advances in Internal May June 2009 Bree Johnston, MD MPH Professor of Clinical bree.johnston@ucsf.edu Methodology Clinically important for

More information

Behavioral Issues in Dementia. March 27, 2014 Dylan Wint, M.D.

Behavioral Issues in Dementia. March 27, 2014 Dylan Wint, M.D. Behavioral Issues in Dementia March 27, 2014 Dylan Wint, M.D. OVERVIEW Key points Depression Definitions and detection Treatment Psychosis Definitions and detection Treatment Agitation SOME KEY POINTS

More information

GALANTAMINE. THERAPEUTICS Brands Razadyne Razadyne ER see index for additional brand names

GALANTAMINE. THERAPEUTICS Brands Razadyne Razadyne ER see index for additional brand names GALANTAMINE THERAPEUTICS Brands Razadyne Razadyne ER see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: acetylcholine multi-modal; enzyme inhibitor; receptor PAM (ACh-MM)

More information

Dementia Care Pathway

Dementia Care Pathway Document level: West Locality Code: CC41 Issue number: 1 Dementia Care Pathway Lead executive Authors details Type of document Target audience Document purpose Medical Director Dr Anushta Sivananthan Dr

More information

Cholinesterase inhibitors for Alzheimer s disease (Review)

Cholinesterase inhibitors for Alzheimer s disease (Review) Birks J This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2008, Issue 3 http://www.thecochranelibrary.com 1 T A B L E O

More information

Silvia Duong, 1,2 Kam-Tong Yeung, 1 and Feng Chang 1,3. 1. Introduction

Silvia Duong, 1,2 Kam-Tong Yeung, 1 and Feng Chang 1,3. 1. Introduction Aging Research Volume 2015, Article ID 570410, 6 pages http://dx.doi.org/10.1155/2015/570410 Research Article Intramuscular Olanzapine in the Management of Behavioral and Psychological Symptoms in Hospitalized

More information

Aricept, Exelon and Reminyl the new drugs for Alzheimer s disease

Aricept, Exelon and Reminyl the new drugs for Alzheimer s disease PBO 930022142 NPO 049-191 Aricept, Exelon and Reminyl the new drugs for Alzheimer s disease Aricept, Exelon and Reminyl are not cures for Alzheimer s disease. However, they can temporarily slow down the

More information

Safety Profile Assessment of Risperidone and Olanzapine in Long-Term Care Patients with Dementia

Safety Profile Assessment of Risperidone and Olanzapine in Long-Term Care Patients with Dementia ORIGINAL STUDIES Safety Profile Assessment of Risperidone and Olanzapine in Long-Term Care Patients with Dementia Harlan Martin, RPh, CCP, FASCP, Michael P. Slyk, PharmD, FASCP, Sheila Deymann, PharmD,

More information

TITLE: Memantine in Combination with Cholinesterase Inhibitors for Alzheimer s Disease: Clinical Effectiveness

TITLE: Memantine in Combination with Cholinesterase Inhibitors for Alzheimer s Disease: Clinical Effectiveness TITLE: Memantine in Combination with Cholinesterase Inhibitors for Alzheimer s Disease: Clinical Effectiveness DATE: 30 October 2008 RESEARCH QUESTION: What is the evidence for using memantine in combination

More information

It is only in the past decade that pharmacologic

It is only in the past decade that pharmacologic IS THERE TREATMENT FOR ALZHEIMER S DISEASE? Gary M. Levin, PharmD, BCPP, FCCP * ABSTRACT There are now 5 approved drugs for the primary symptoms of Alzheimer s disease (AD), 4 of which inhibit acetylcholinesterase

More information

The efficacy of Rivastigmine in the management of the behavioral and psychological symptoms of lewy body dementia- a review of literature

The efficacy of Rivastigmine in the management of the behavioral and psychological symptoms of lewy body dementia- a review of literature Review article: The efficacy of Rivastigmine in the management of the behavioral and psychological symptoms of lewy body dementia- a review of literature Dr. Ivan Netto 1, Aditya Iyer 2, Dr. Prathamesh

More information

Community Pharmacy Dementia Audit

Community Pharmacy Dementia Audit Community Pharmacy Dementia Audit Introduction To comply with the NHS contractual requirements associated with the Clinical Governance Essential Service, pharmacy contractors must perform an annual practice

More information

Essential Shared Care Agreement Drugs for Dementia

Essential Shared Care Agreement Drugs for Dementia Ref No. E052 Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient s GP 2. put one copy in care plan 3. give

More information

ALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey

ALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey ALZHEIMER S DISEASE Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey Topics Covered Demography Clinical manifestations Pathophysiology Diagnosis Treatment Future trends Prevalence and Impact

More information